PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference
PDL BioPharma to Present at Two Upcoming Investor Conferences
PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results
PDL BioPharma Announces $30 Million Share Repurchase Program
PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017